6:00 PM
 | 
Sep 25, 2012
 |  BC Extra  |  Company News

Depomed sues FDA over Orphan exclusivity for PHN drug

Depomed Inc. (NASDAQ:DEPO) sued FDA in the U.S. District Court for the District of Columbia seeking to force the agency to grant Orphan Drug exclusivity for Gralise gabapentin to manage postherpetic neuralgia. In its complaint,...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >